Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,646 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

The Effects of Low Dose Atropine on Choroidal Thickness

NCT03544827
View directory record Official record
Conditions
Myopia
Interventions
Atropine
Drug
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years to 35 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 20, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT04523129
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 20, 2026, 4:47 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

NCT07168902
View directory record Official record
Conditions
Glaucoma
Interventions
BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Glendale, California • Newport Beach, California • Pasadena, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 20, 2026, 4:47 PM EDT
Completed Not applicable Interventional

Continuous Quality Improvement (CQI) Pilot Study Evaluating the Utility of an Educational Video

NCT02062853
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Video Group, Verbal Group
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 20, 2026, 4:47 PM EDT
Withdrawn Phase 4 Interventional

Topical Timolol for the Treatment of Benign Vascular Periocular Lesions

NCT01250457
View directory record Official record
Conditions
Benign Vascular Periocular Lesions
Interventions
topical Timolol
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 20, 2026, 4:47 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking

NCT06235567
View directory record Official record
Conditions
Keratoconus
Interventions
Dextenza 0.4Mg Ophthalmic Insert, topical prednisolone acetate 1% (PredForte) eye drops
Drug
Lead sponsor
Maanasa Indaram, MD
Other
Eligibility
13 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 4:47 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia)

NCT00346502
View directory record Official record
Conditions
Dysplastic Nevus Syndrome
Interventions
20% betulinic acid ointment, BA
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 20, 2026, 4:47 PM EDT
Recruiting Phase 4 Interventional

Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study

NCT04207931
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions
Topical steroid class I-II, Triamcinolone Acetonide, Doxycyline, Minoxidil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 20, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

ALC-919 For The Treatment Of Common Warts

NCT02483455
View directory record Official record
Conditions
Verruca Vulgaris
Interventions
2014-ALC-919-US, Vehicle-Control Topical Solution
Drug
Lead sponsor
Veloce BioPharma LLC
Industry
Eligibility
8 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Fort Washington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 20, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Assessing Local Cutaneous Effects of SB204

NCT02250430
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 20, 2026, 4:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Natrox Oxygen Wound Therapy on Non-healing Wounds and Implication of Remote Monitoring and Telehealth for Management in the Home.

NCT04746573
View directory record Official record
Conditions
Non-healing Wounds
Interventions
Natrox Topical Oxygen Therapy
Device
Lead sponsor
Inotec AMD Limited
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 20, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)

NCT01188928
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriol plus betamethasone, Betamethasone-17,21-dipropionate, Calcipotriene, Topical suspension vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
59
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 20, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose, Three-Way, Three-Sequence, Crossover BA Study of Azithromycin Oleogel

NCT05796362
View directory record Official record
Conditions
Infectious Disease, Drug Effect, Clinical Infection
Interventions
Azithromycin Oleogel (Oral and Rectal)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 20, 2026, 4:47 PM EDT
Completed Phase 4 Interventional Results available

Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis

NCT02340169
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Topicort® (desoximetasone) Topical Spray, 0.25%
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 20, 2026, 4:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Topical Cyclosporine and Disease Progression

NCT00567983
View directory record Official record
Conditions
Disease Progression, Disease Severity, Staining, Schirmers, OSDI
Interventions
Restasis, Endura
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Oct 20, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters

NCT00231153
View directory record Official record
Conditions
Infection
Interventions
Omiganan 1% gel, Povidone-Iodine 10%
Drug
Lead sponsor
Cadence Pharmaceuticals
Industry
Eligibility
13 Years and older
Enrollment
1,859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
36
States / cities
Mobile, Alabama • Phoenix, Arizona • Arcadia, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2009 · Synced Oct 20, 2026, 4:47 PM EDT
Recruiting Early Phase 1 Interventional

Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis

NCT03439865
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Ivacaftor, standard of care treatment
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 20, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis

NCT03645057
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole, Tacrolimus 0.03% Ointment
Drug
Lead sponsor
University of Rochester
Other
Eligibility
2 Years to 15 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 20, 2026, 4:47 PM EDT
Not yet recruiting Not applicable Interventional

Cyanoacrylate Skin Adhesive After Mohs Surgery or Wide Local Excision

NCT07844681
View directory record Official record
Conditions
Surgical Site Infection, Skin Cancer, Wound Healing
Interventions
Cyanoacrylate Skin Adhesive, Fast Gut Running Epidermal Suture Closure, Vicryl Rapide Running Epidermal Suture Closure, Prolene Running Epidermal Suture Closure
Device · Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection

NCT02068430
View directory record Official record
Conditions
Corneal Ulcers
Interventions
Riboflavin 0.1%, UV-X™ Illumination System
Drug · Other
Lead sponsor
Stephen Trokel
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 20, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

The Fibrin Pad CV Phase III Study

NCT02040428
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
EVARREST™ Fibrin Sealant Patch, Topical hemostat
Biological
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 20, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis

NCT02553798
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Glycopyrronium Topical Wipes
Drug
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
9 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
40
States / cities
Mobile, Alabama • Rogers, Arkansas • Encinitas, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 20, 2026, 4:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

NCT03414645
View directory record Official record
Conditions
Dry Eye, Graft-versus-host-disease, Ocular Discomfort
Interventions
CAM-101 10%, Vehicle Control, CAM-101 30%
Biological
Lead sponsor
Cambium Bio Limited
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Palo Alto, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 20, 2026, 4:47 PM EDT
Recruiting Phase 3 Interventional

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT06807281
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Abrocitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
11
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 4:47 PM EDT